PHASE 3 | NOW ENROLLING
Evaluating the novel BET inhibitor pelabresib ( CPI-0610 ) + ruxolitinib in patients with myelofibrosis who are JAK-inhibitor naïve
A phase 3 , global , randomized , double-blind trial of first-line treatment
Study population ( N =~ 310 )
JAKi-naïve patients with symptomatic myelofibrosis requiring treatment
Prespecified subgroup analyses
Patients stratified by prognostic risk , platelet count , and spleen volume
Double-blind randomization ( 1:1 ) Treatment arms
Pelabresib + ruxolitinib
Placebo + ruxolitinib
Open to JAKi-naïve patients with primary myelofibrosis ( PMF ), post-polycythemia vera MF ( PPV-MF ), or post-essential thrombocytopenia MF ( PET-MF ) and symptomatic disease , advanced MF requiring therapy , and splenomegaly .
BET = bromodomain and extra-terminal domain ; JAK = Janus kinase ; JAKi = JAK inhibitor . Please visit manifestclinicaltrials . com or ClinicalTrials . gov for full trial information , including full eligibility criteria .
Pelabresib is an investigational new drug and not yet approved by any regulatory authority .
Learn more about opportunities for investigators and patient enrollment : Visit manifestclinicaltrials . com or ClinicalTrials . gov ( NCT04603495 ) Or contact Debbie . Johnson @ constellationpharma . com
Open your camera app and point it here to visit manifestclinicaltrials . com
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer .
© 2021 Constellation Pharmaceuticals , Inc . All rights reserved . MED-US-PELA-003-2021FEB